A biotechnology firm have received a grant of half a million dollars to further their research into finding a way of treating juvenile diabetes. The funding, provided by the US Food and Drug Administration (FDA), will allow ImmunoMod LLC to progress their research.
The company will now advance to human trials of their diabetic drug, to be conducted at the Children’s Hospital of Philadelphia. The FDA have previously ruled that tests of this type may not be conducted in the same area as the facility itself.
ImmunoMod was founded in 2006 with the express aim of treating juvenile diabetes. Although a much smaller problem than obesity-influenced type 2 diabetes, type 1 still affects 20,000 American children per annum. Type 1 is also more dangerous, and most patients require daily insulin injections.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…